IDC441 / Prestige BioPharma - LARVOL DELTA

Prestige Biopharma IDC-Aptis, ADC anticancer new drug joint development MOU [Google translation] (Medipana) - "Prestige Biopharma IDC...announced on the 26th that it has signed a strategic business agreement with Dong-A ST subsidiary Aptis...for the development of next-generation ADC anticancer drugs. The signing ceremony was held at the Aptis Yongin Research Institute, attended by IDC CEO Sang-seok Koh and Aptis CEO Tae-dong Han....This is the first time that Prestige Biopharma IDC has signed an MOU for joint research on antibody-drug conjugates (ADCs). The agreement with Aptis focuses on joint research on ADCs using two antibodies, including IDC’s new ADC pipeline, ‘IDC441’, within the year."

Licensing / partnership • Oncology • Solid Tumor

Prestige Biopharma unveils pipeline lineup at Bio USA [Google translation] (HIT News) - "PBP1510 phase 1·2a, interim analysis announced this year...Prestige Biopharma Group announced on the 7th that it held a press conference at a separate booth prepared at the '2024 Bio International Convention...PBP1710, which is in the preclinical stage and is being introduced one after another in international academic journals and academic societies...CEO Koh explained that IDC441 is a new concept ADC that combines the function of suppressing tumor development by controlling the microenvironment around the tumor, unlike the existing ADC mechanism of action that is internalized from the cell surface....Koh also disclosed the clinical progress of PBP1510, a new pancreatic cancer antibody drug being developed by Prestige Biopharma. Currently, 14 patients have received the medication at the Spanish hospital, which opened first, and the US site is undergoing final preparations and is scheduled to begin administering the medication this month."

P1/2 data • Preclinical • Trial status • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor